Haemonetics Co. (NYSE:HAE) – Analysts at William Blair increased their FY2019 earnings per share estimates for Haemonetics in a report issued on Tuesday, November 6th. William Blair analyst B. Weinstein now forecasts that the medical instruments supplier will post earnings of $2.34 per share for the year, up from their previous estimate of $2.30. William Blair also issued estimates for Haemonetics’ Q4 2019 earnings at $0.57 EPS, Q1 2020 earnings at $0.59 EPS, Q2 2020 earnings at $0.71 EPS, Q3 2020 earnings at $0.83 EPS and Q4 2020 earnings at $0.77 EPS.

Haemonetics (NYSE:HAE) last released its earnings results on Tuesday, November 6th. The medical instruments supplier reported $0.56 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.54 by $0.02. The firm had revenue of $241.58 million for the quarter, compared to the consensus estimate of $233.44 million. Haemonetics had a net margin of 2.26% and a return on equity of 16.04%. The company’s revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.48 EPS.

A number of other analysts also recently weighed in on HAE. Barrington Research upped their target price on shares of Haemonetics from $90.00 to $118.00 and gave the stock an “outperform” rating in a research report on Thursday, August 9th. Zacks Investment Research raised shares of Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 target price on the stock in a research report on Friday, October 12th. Morgan Stanley upped their target price on shares of Haemonetics from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 8th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $125.00 target price on shares of Haemonetics in a research report on Tuesday, August 7th. Finally, TheStreet downgraded shares of Haemonetics from a “b” rating to a “c+” rating in a research report on Monday, August 20th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and two have assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $113.20.

NYSE:HAE opened at $111.61 on Thursday. The stock has a market capitalization of $5.95 billion, a PE ratio of 59.68, a price-to-earnings-growth ratio of 3.67 and a beta of 1.09. The company has a current ratio of 2.92, a quick ratio of 1.94 and a debt-to-equity ratio of 0.47. Haemonetics has a 1-year low of $53.74 and a 1-year high of $117.56.

In related news, CFO William P. Mr. Burke sold 841 shares of the stock in a transaction dated Thursday, October 25th. The shares were sold at an average price of $46.76, for a total transaction of $39,325.16. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Pedro P. Granadillo sold 30,824 shares of the stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $111.83, for a total transaction of $3,447,047.92. The disclosure for this sale can be found here. Insiders have sold a total of 62,653 shares of company stock worth $6,973,391 over the last three months. 1.04% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in HAE. CIBC Asset Management Inc purchased a new stake in Haemonetics during the 3rd quarter valued at about $219,000. Wagner Bowman Management Corp purchased a new stake in Haemonetics during the 2nd quarter valued at about $224,000. Arjuna Capital purchased a new stake in Haemonetics during the 2nd quarter valued at about $224,000. Granahan Investment Management Inc. MA purchased a new stake in Haemonetics during the 2nd quarter valued at about $229,000. Finally, Welch & Forbes LLC purchased a new stake in Haemonetics during the 3rd quarter valued at about $229,000. 96.44% of the stock is currently owned by institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

See Also: Growth Stocks, What They Are, What They Are Not

Earnings History and Estimates for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.